Prognostic significance of Minichromosome maintenance protein 7 and Geminin expression in patients with 109 soft tissue sarcomas

Hamamoto,Yuki; Shomori,Kohei; Nosaka,Kanae; Haruki,Tomohiro; Teshima,Ryota; Ito,Hisao

doi:10.3892/ol_00000123

Prognostic significance of Minichromosome maintenance protein 7 and Geminin expression in patients with 109 soft tissue sarcomas

Authors:
- Yuki Hamamoto
- Kohei Shomori
- Kanae Nosaka
- Tomohiro Haruki
- Ryota Teshima
- Hisao Ito
View Affiliations

Affiliations: Division of Organ Pathology, Department of Microbiology and Pathology, Faculty of Medicine, Tottori University, Tottori 683-8503, Japan
Published online on: July 1, 2010 https://doi.org/10.3892/ol_00000123
Pages: 703-709

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Minichromosome maintenance complex (MCM2-7) and Geminin are important in the prevention of DNA re-replication in the cell cycle, and are also prognostic markers for numerous human malignancies. The present study examined Minichromosome maintenance protein 7 (MCM7) and Geminin expression in human soft tissue sarcomas (STSs) to clarify their correlation to the clinicopathological factors. Immunohistochemistry was performed to detect the expression of MCM7, Geminin and Ki-67 on paraffin-embedded sections of 109 STSs. Labeling indices (LIs) of the molecules were evaluated in the tumors. Higher LIs of MCM7, Geminin and Ki-67 were significantly correlated with distant metastasis (P<0.01), histological grade (P<0.01) and poor prognosis (P<0.01), respectively. LIs of MCM7 and Geminin were significantly correlated with Ki-67 LIs, (MCM7/Ki-67: rs=0.745, P<0.01 and Geminin/Ki-67: rs=0.604, P<0.01). Multivariate analyses showed that the higher LIs of Geminin, but not MCM7 and Ki-67, were shown to be an independent factor of poorer prognosis (relative risk 2.72, P=0.013). The immunohistochemical expression of MCM7 and Geminin may be novel and useful markers for evaluating the prognosis in patients with human STS.

View Figures

View References

1	Stefanovski PD, Bidoli E, De Paoli A, et al: Prognostic factors in soft tissue sarcomas: a study of 395 patients. Eur J Surg Oncol. 28:153–164. 2002. View Article : Google Scholar : PubMed/NCBI
2	Tomita Y, Aozasa K, Myoui A, et al: Histologic grading in soft-tissue sarcomas – an analysis of 194 cases including agnor count and mast-cell count. Int J Cancer. 54:194–199. 1993.
3	Levine EA: Prognostic factors in soft tissue sarcoma. Semin Surg Oncol. 17:23–32. 1999. View Article : Google Scholar
4	Engellau J, Bendahl PO, Persson A, et al: Improved prognostication in soft tissue sarcoma: independent information from vascular invasion, necrosis, growth pattern, and immunostaining using whole-tumor sections and tissue microarrays. Hum Pathol. 36:994–1002. 2005. View Article : Google Scholar
5	Ahlen J, Wejde J, Brosjo O, et al: Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma. Clin Cancer Res. 11:206–216. 2005.PubMed/NCBI
6	Bramwell VHC, Tuck AB, Wilson SM, et al: Expression of osteopontin and HGF/Met in adult soft tissue tumors. Cancer Biology and Therapy. 4:1336–1341. 2005. View Article : Google Scholar : PubMed/NCBI
7	Huuhtanen RL, Blomqvist CP, Bohling TO, et al: Expression of cyclin A in soft tissue sarcomas correlates with tumor aggressiveness. Cancer Res. 59:2885–2890. 1999.PubMed/NCBI
8	Jensen V, Sorensen FB, Bentzen SM, et al: Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas. Histopathology. 32:536–546. 1998. View Article : Google Scholar
9	Lopes JM, Nesland JM, Reis JS and Holm R: Differential Ki67 and bcl-2 immunoexpression in solid-glandular and spindle cell components of biphasic synovial sarcoma: a double immunostaining assessment with cytokeratin and vimentin. Histopathology. 40:464–471. 2002. View Article : Google Scholar
10	Oda Y, Tateishi N, Matono H, et al: Chemokine receptor CXCR4 expression is correlated with VEGF expression and poor survival in soft-tissue sarcoma. Int J Cancer. 124:1852–1859. 2009. View Article : Google Scholar : PubMed/NCBI
11	Ottaiano A, De Chiara A, Perrone F, et al: Prognostic value of CD40 in adult soft tissue sarcomas. Clin Cancer Res. 10:2824–2831. 2004. View Article : Google Scholar : PubMed/NCBI
12	Peiper M, Sato T, Zurakowski D, et al: CD44s expression is associated with improved survival in soft tissue sarcoma. Anticancer Res. 24:1053–1056. 2004.PubMed/NCBI
13	Sato O, Wada T, Kawai A, et al: Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas – a clinicopathologic study of 281 cases. Cancer. 103:1881–1890. 2005.
14	Tsiatis AC, Herceg ME, Keedy VL, et al: Prognostic significance of c-Myc expression in soft tissue leiomyosarcoma. Mod Pathol. 22:1432–1438. 2009. View Article : Google Scholar : PubMed/NCBI
15	Vesely K, Jurajda M, Nenutil R and Vesela M: Expression of p53, cyclin D1 and EGFR correlates with histological grade of adult soft tissue sarcomas: a study on tissue microarrays. Neoplasma. 56:239–244. 2009. View Article : Google Scholar : PubMed/NCBI
16	Yamaga K, Osaki M, Kidani K, Shomori K, Yoshida H and Ito H: High expression of enhancer of zeste homologue 2 indicates poor prognosis in patients with soft tissue sarcomas. Mol Med Rep. 1:633–639. 2008.PubMed/NCBI
17	Yudoh K, Kanamori N, Ohmori K, Yasuda T, Aoki M and Kimura T: Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer. 84:1610–1615. 2001. View Article : Google Scholar : PubMed/NCBI
18	Zhang B, Tomita Y, Ch’ng E, et al: Prognostic significance of phosphorylated FOXO1 expression in soft tissue sarcoma. Ann Surg Oncol. 16:1925–1937. 2009. View Article : Google Scholar : PubMed/NCBI
19	Osaki M, Yamashita H, Shomori K, Yoshida H and Ito H: Expression of minichromosome maintenance-2 in human malignant fibrous histiocytomas: Correlations with Ki-67 and P53 expression and apoptosis. Int J Mol Med. 10:161–168. 2002.PubMed/NCBI
20	Lindner K, Gregan J, Montgomery S and Kearsey SE: Essential role of MCM proteins in premeiotic DNA replication. Mol Biol Cell. 13:435–444. 2002. View Article : Google Scholar : PubMed/NCBI
21	Nishitani H and Lygerou Z: Control of DNA replication licensing in a cell cycle. Genes to Cells. 7:523–534. 2002. View Article : Google Scholar : PubMed/NCBI
22	Ishimi Y: A DNA helicase activity is associated with an MCM4, -6 and -7 protein complex. J Biol Chem. 272:24508–24513. 1997. View Article : Google Scholar : PubMed/NCBI
23	Forsburg SL: Eukaryotic MCM proteins: beyond replication initiation. Microbiol Mol Biol Rev. 68:109–131. 2004. View Article : Google Scholar : PubMed/NCBI
24	McGarry TJ and Kirschner MW: Geminin, an inhibitor of DNA replication, is degraded during mitosis. Cell. 93:1043–1053. 1998. View Article : Google Scholar : PubMed/NCBI
25	Lygerou Z and Nurse P: Cell cycle. License withheld – Geminin blocks DNA replication. Science. 290:2271–2273. 2000.PubMed/NCBI
26	Wohlschlegel JA, Kutok JL, Weng AP and Dutta A: Expression of geminin as a marker of cell proliferation in normal tissues and malignancies. Am J Pathol. 161:267–273. 2002. View Article : Google Scholar : PubMed/NCBI
27	Gonzalez MA, Pinder SE, Callagy G, et al: Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer. J Clin Oncol. 21:4306–4313. 2003. View Article : Google Scholar : PubMed/NCBI
28	Hashimoto K, Araki K, Osaki M, et al: MCM2 and Ki-67 expression in human lung adenocarcinoma: prognostic implications. Pathobiology. 71:193–200. 2004. View Article : Google Scholar : PubMed/NCBI
29	Nariculam J, Loddo M, Masters J, Williams G and Feneley M: MCM-2 expression in clinically localised prostate cancer. Eur Urol Suppl. 7:7382008. View Article : Google Scholar
30	Padmanabhan V, Callas P, Philips G, Trainer TD and Beatty BG: DNA replication regulation protein MCM7 as a marker of proliferation in prostate cancer. J Clin Pathol. 57:1057–1062. 2004. View Article : Google Scholar : PubMed/NCBI
31	Nishihara K, Shomori K, Fujioka S, et al: Minichromosome maintenance protein 7 in colorectal cancer: Implication of prognostic significance. Int J Oncol. 33:245–251. 2008.PubMed/NCBI
32	Shimizu M, Nikaido T, Kato K, et al: Expression of replication-licensing factors MCM2 and MCM3 in normal endometrium and endometrial carcinomas. In: 9th International Menopause Society World Congress on the Menopause; pp. 159–162. 1999
33	Torres-Rendon A, Roy S, Craig GT and Speight PM: Expression of MCM2, geminin and Ki67 in normal oral mucosa, oral epithelial dysplasias and their corresponding squamous-cell carcinomas. Br J Cancer. 100:1128–1134. 2009. View Article : Google Scholar : PubMed/NCBI
34	Vargas PA, Cheng Y, Barrett AW, Craig GT and Speight PM: Expression of Mcm-2, Ki-67 and geminin in benign and malignant salivary gland tumours. J Oral Pathol Med. 37:309–318. 2008. View Article : Google Scholar : PubMed/NCBI
35	Salabat MR, Melstrom LG, Strouch MJ, et al: Geminin is overexpressed in human pancreatic cancer and downregulated by the bioflavanoid apigenin in pancreatic cancer cell lines. Mol Carcinogen. 47:835–844. 2008. View Article : Google Scholar : PubMed/NCBI
36	Shrestha P, Saito T, Hama S, et al: Geminin: a good prognostic factor in high-grade astrocytic brain tumors. Cancer. 109:949–956. 2007. View Article : Google Scholar : PubMed/NCBI
37	Nishihara K, Shomori K, Tamura T, Fujioka S, Ogawa T and Ito H: Immunohistochemical expression of geminin in colorectal cancer: Implication of prognostic significance. Oncol Rep. 21:1189–1195. 2009.PubMed/NCBI
38	Gonzalez MA, Tachibana KK, Chin SF, et al: Geminin predicts adverse clinical outcome in breast cancer by reflecting cell-cycle progression. J Pathol. 204:121–130. 2004. View Article : Google Scholar : PubMed/NCBI
39	Fletcher CDM, Unni KK and Mertens F: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft tissue and Bone. IARC Press; Lyon: 2002
40	Guillou L, Coindre JM, Bonichon F, et al: Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 15:350–362. 1997.
41	Eisenman RN: Deconstructing Myc. Genes Dev. 15:2023–2030. 2001. View Article : Google Scholar : PubMed/NCBI
42	Shohet JM, Hicks MJ, Plon SE, et al: Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma. Cancer Res. 62:1123–1128. 2002.PubMed/NCBI
43	Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U and Stein H: Cell-cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal-antibody Ki-67. J Immunol. 133:1710–1715. 1984.PubMed/NCBI
44	Hoos A, Stojadinovic A, Mastorides S, et al: High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas. Cancer. 92:869–874. 2001. View Article : Google Scholar : PubMed/NCBI
45	Hasegawa T, Yamamoto S, Yokoyama R, Umeda T, Matsuno Y and Hirohashi S: Prognostic significance of grading and staging systems using MIB-1 score in adult patients with soft tissue sarcoma of the extremities and trunk. Cancer. 95:843–851. 2002. View Article : Google Scholar : PubMed/NCBI